Why the study?
Direct oral factor Xa inhibitors have emerged as potential alternatives to LMWH for cancer-associated VTE, with initial clinical studies recently published.
Do direct oral factor Xa inhibitors prevent recurrent VTE and improve safety in patients with cancer-associated thrombosis compared to LMWH?
Do direct oral factor Xa inhibitors prevent recurrent VTE and improve safety in patients with cancer-associated thrombosis compared to LMWH?
Direct oral factor Xa inhibitors are an effective and convenient alternative to LMWH for managing cancer-associated thrombosis, though patient-specific bleeding risks must be considered.
BACKGROUND: Venous thromboembolism (VTE) is a frequent cause of morbidity and mortality in patients with cancer. Moreover, management of VTE is frequently connected with complications, namely risk of recurrent VTE and bleeding. Low molecular weight heparins (LMWH) therapy administrated for 3-6 months is currently considered a standard for the treatment of cancer-associated VTE (CA-VTE). Direct oral factor Xa inhibitors (FXaI) apixaban, edoxaban and rivaroxaban have emerged as a new possibility for long-term antithrombotic therapy for VTE. These agents expose several advantages in individuals with cancer, and might overcome several disadvantages connected with LMWH therapy. PURPOSE: First clinical studies with oral FXaI for the treatment of CA-VTE with very promising results were recently published. The article summarizes current data regarding the use of oral FXaI in the treatment of CA-VTE.
No takes yet. Share an insight, caveat, or question.
Grilusová et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: